Compare Alcon AG (ALC) vs US Bancorp (USB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs US Bancorp — how do they compare? Alcon AG trades at $66.81 (market cap $32.69B), while US Bancorp trades at $61.16 (market cap $97.97B). The key difference: US Bancorp is far larger — about 3× Alcon AG's market cap, and US Bancorp pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| ALC | USB | |
|---|---|---|
Market Cap | $32.69B | $97.97B |
Sector | Health | Financials |
52-Week High | $92.22 | $62.89 |
52-Week Low | $62.02 | $43.94 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
U.S. Bancorp (USB) trades at $62.89, up 1.88% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company reported 2025 net income of $7.57 billion, with a net margin of 27.04%, and maintains a solid dividend history, including a recent $0.52 per share payout. Analyst consensus is mixed but leans positive, with a price target of $66.64.
USB's outlook is supported by robust profitability and strategic partnerships, but risks include interest rate sensitivity and competitive pressures. The stock offers value with a P/E of 13.17, though investors should monitor net cash flow trends and economic conditions affecting banking sector performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
